E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
A study of the effects of dapagliflozin on ambulatory aortic pressure, arterial stiffness and urine albumin excretion in patients with type 2 diabetes mellitus. |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029505 |
E.1.2 | Term | Non-insulin-dependent diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10027433 |
E.1.2 | Term | Metabolism and nutrition disorders |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of the present study is to investigate the effect of dapagliflozin on ambulatory aortic pressure in patients with type 2 DM. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives are to investigate the effects of dapagliflozin on ambulatory arterial stiffness, and urine albumin excretion. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age >18 and <70 years old 2. Type 2 diabetes mellitus 3. Glycated hemoglobin >7% and <9% 4. Patients on stable dose of metformin of at least 1500 mg for the past 3 months. 5. Patient to provide informed consent
|
|
E.4 | Principal exclusion criteria |
1. Hypovolemic patients. 2. Patients on loop diuretics. 3. Patients with low BP (office SBP <110 mmHg) or orthostatic hypotension (BP drop >20 mmHg and SBP <110 mmHg in standing position at 1 min). 4. Patients on antidiabetic drugs other than metformin. 5. Secondary hypertension. 6. Stage 2 hypertension or higher (office SBP ≥160 mmHg or DBP ≥100 mmHg). 7. Chronic kidney disease stage 3 or higher (GFR<60 mL/min/1.73 m2). 8. Myocardial infarction or unstable angina episode within the past 3 months, or congestive heart failure class III-IV according to New York Heart Association criteria. 9. Pregnancy or childbearing potential [defined as women which have entered menses and are not post-menopausal (menopause is defined as the absence of menses for at least 12 months without any other medical cause in women of typical age) or women that have been subjected to permanent sterilization (ie. tubal ligation, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)]. 10. History of liver disease or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN or total bilirubin >2.0 mg/dL. 11. History of malignancy of any organ system (resected basal cell carcinoma considered cured is exempted) within the past 5 years prior to Visit 1 (V1). 12. History of drug or alcohol abuse within the last one year. 13. Any contraindication or history of hypersensitivity to the study drug or to drugs with similar chemical structures. 14. Any other surgical or medical condition that, in the opinion of the investigator, place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirements of the study or completing the trial period. 15. Intake of an investigational drug in another trial within 30 days prior to Visit 1 (V1).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The difference between the groups of dapagliflozin and placebo in the change of 24-hour systolic aortic pressure at study-end |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint will be recorded with Mobil-O-Graph for the period between visit 1 and end of study (12 weeks treatment) |
|
E.5.2 | Secondary end point(s) |
Secondary end-points would include the difference between the groups of dapagliflozin and placebo in the change of the following parameters between visit 1 and end of study (12 weeks treatment): 1. 24-hour central aortic DBP. 2. 24-hour brachial SBP and DBP. 3. 24-hour AIx. 4. 24-hour PWV. 5. Office brachial SBP and DBP. 6. Albumin/creatinine ratio (ACR). 7. Lipid profile (Total-Cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglycerides). 8. HbA1c.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Period between visit 1 and end of study (12 weeks treatment) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |